Elutia Inc. ELUT
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Elutia Inc. (ELUT) is a healthcare company listed in the US with a market value of about $36M. In the twelve months to September 30, 2026 it had revenue of $17M and net income of $54M, a net margin of 320.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is value (2/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 0.7, a 5-year average ROIC of -89%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 80% below the current price.
About Elutia
Elutia is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. Revenue went from $43M in 2019 to $14M in 2024, a decline of about 19.5% a year. It was profitable in 1 of the last 7 years in our data. Its share count rose by 232% over three years (dilution for shareholders).
Score: 1.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17M | — | $14M | $25M | $24M | $47M | $43M | $43M |
| Net income | $54M | $53M | -$54M | -$38M | -$33M | -$25M | -$22M | -$12M |
| Free cash flow | -$51M | -$47M | -$23M | -$22M | -$22M | -$16M | -$14M | -$8M |
| EPS (diluted) | $1.15 | $0.87 | $-1.86 | $-2.07 | $-2.38 | $-2.38 | $-8.88 | $-18.48 |
| Net margin | 320.6% | — | -372.9% | -152.2% | -137.9% | -52.4% | -51.1% | -27.8% |
| ROIC | — | -67.2% | — | — | -142.9% | -56.9% | -23.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Elutia’s P/E ratio?
About 0.7, based on the last twelve months of diluted earnings per share.
Is Elutia stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 80% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Elutia pay a dividend?
Not currently.
Is Elutia a good stock to buy?
We do not give buy or sell advice. Elutia scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.